Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer

Edyta M. Urbanska; Jens B. Sørensen; Linea C. Melchior; Junia C. Costa; Eric Santoni-Rugiu

doi:10.1200/PO.22.00040

Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer

Edyta M. Urbanska, Jens B. Sørensen, Linea C. Melchior, Junia C. Costa, Eric Santoni-Rugiu

Research output: Contribution to journal › Journal article › Research › peer-review

16 Downloads (Pure)

Original language	English
Article number	e2200040
Journal	JCO Precision Oncology
Volume	6
Issue number	6
Number of pages	6
ISSN	2473-4284
DOIs	https://doi.org/10.1200/PO.22.00040
Publication status	Published - 2022

Access to Document

10.1200/PO.22.00040Licence: CC BY-NC-ND

FulltextFinal published version, 678 KBLicence: CC BY-NC-ND

Cite this

Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer. / Urbanska, Edyta M.; Sørensen, Jens B.; Melchior, Linea C.; Costa, Junia C.; Santoni-Rugiu, Eric.

In: JCO Precision Oncology, Vol. 6, No. 6, e2200040, 2022.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{4d75f6bf27e44cee92c7395b89e59986,

title = "Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer",

author = "Urbanska, {Edyta M.} and S{\o}rensen, {Jens B.} and Melchior, {Linea C.} and Costa, {Junia C.} and Eric Santoni-Rugiu",

year = "2022",

doi = "10.1200/PO.22.00040",

language = "English",

volume = "6",

journal = "JCO Precision Oncology",

issn = "2473-4284",

publisher = "American Society of Clinical Oncology",

number = "6",

}

TY - JOUR

T1 - Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer

AU - Urbanska, Edyta M.

AU - Sørensen, Jens B.

AU - Melchior, Linea C.

AU - Costa, Junia C.

AU - Santoni-Rugiu, Eric

PY - 2022

Y1 - 2022

U2 - 10.1200/PO.22.00040

DO - 10.1200/PO.22.00040

M3 - Journal article

C2 - 35797511

VL - 6

JO - JCO Precision Oncology

JF - JCO Precision Oncology

SN - 2473-4284

IS - 6

M1 - e2200040

ER -